Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CERS
CERS logo

CERS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cerus Corp (CERS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.830
1 Day change
-6.91%
52 Week Range
3.150
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Cerus Corp is not a strong buy right now for a Beginner with a long-term focus and $50,000-$100,000 to invest. The technical setup is bullish in the short term, but the stock has already moved up, options sentiment is strongly bullish, and there is no recent news or financial data to confirm durable fundamental momentum. Given the investor profile and the lack of clear long-term conviction, the best call is to hold and wait for better confirmation rather than buy aggressively now.

Technical Analysis

CERS is showing a constructive short-term trend. MACD histogram is positive and expanding, and the moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200), which supports upward momentum. However, RSI_6 at 79.059 indicates the stock is extended, even if the provided interpretation labels it neutral. Price is trading near resistance at R1 2.897 and below R2 3.049, while support sits at 2.653 and 2.409. The pattern-based forecast also points to weakness over the next week and month, which tempers the near-term bullish chart structure.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is very bullish. The put-call ratios for both open interest and volume are extremely low, showing strong call dominance and a market leaning toward upside expectations. Implied volatility is elevated at 81.39, with historical volatility at 101.35, suggesting the options market is pricing in meaningful movement. This supports bullish sentiment, but the lack of a confirmed proprietary buy signal makes it less compelling as an immediate entry for a beginner long-term investor.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
8

Positive Catalysts

  • ["BTIG upgraded Cerus to Buy from Neutral with a $4 price target on 2026-05-01.", "Bullish moving average alignment suggests positive trend continuation.", "MACD histogram is positive and expanding, indicating strengthening momentum.", "Options data shows strong call-driven sentiment with very low put-call ratios."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh event-driven catalyst.", "No recent significant hedge fund or insider buying trends.", "No recent congress trading data available.", "RSI is elevated, suggesting the move may be stretched.", "Pattern-based stock trend analysis suggests downside over the next day, week, and month.", "No AI Stock Picker or SwingMax buy signal today."]

Financial Performance

No usable latest-quarter financial snapshot was provided because of a data error, so there is no reliable quarter-over-quarter or year-over-year growth assessment available. The latest quarter season cannot be confirmed from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment has improved recently. BTIG upgraded Cerus to Buy from Neutral and set a $4 price target on 2026-05-01, which is a positive change in Wall Street view. Overall, the pro case is that the upgrade and bullish technicals support upside, while the con case is that the stock lacks fresh catalysts, lacks insider/hedge fund confirmation, and does not have a strong fundamental update to justify an immediate long-term commitment.

Wall Street analysts forecast CERS stock price to rise
4 Analyst Rating
Wall Street analysts forecast CERS stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.040
sliders
Low
4
Averages
4.5
High
5
Current: 3.040
sliders
Low
4
Averages
4.5
High
5
BTIG
Neutral
to
Buy
upgrade
$4
AI Analysis
2026-05-01
Reason
BTIG
Price Target
$4
AI Analysis
2026-05-01
upgrade
Neutral
to
Buy
Reason
BTIG upgraded Cerus to Buy from Neutral with a $4 price target.
TD Cowen
TD Cowen
Buy
maintain
$5
2025-12-23
Reason
TD Cowen
TD Cowen
Price Target
$5
2025-12-23
maintain
Buy
Reason
TD Cowen says that Cerus' Intercept Fibrinogen Complex franchise represents an underappreciated long-term growth engine. The firm expects the newly announced BCA partnership to materially accelerate its adoption, scalability, and profitability across the U.S. blood center ecosystem. TD Cowen has increased confidence in the sustainability of Cerus' double digit revenue growth trajectory and views the current discounted valuation as attractive. The firm has a Buy rating on the shares with a price target of $5.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CERS
Unlock Now

People Also Watch